Evaluation of Clonality and Carbapenem Resistance Mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus Complex and Enterobacteriaceae Isolates Collected in European and Mediterranean Countries and Detection of Two Novel β-Lactamases, GES-22 and VIM-35

ABSTRACT We evaluated doripenem-resistant Acinetobacter baumannii-Acinetobacter calcoaceticus complex (ACB; n = 411) and Enterobacteriaceae (n = 92) isolates collected from patients from 14 European and Mediterranean countries during 2009 to 2011 for the presence of carbapenemase-encoding genes and clonality. Following susceptibility testing, carbapenem-resistant (doripenem MIC, >2 μg/ml) isolates were screened for carbapenemases. New β-lactamase genes were expressed in a common background and susceptibility was tested. Class 1 integrons were sequenced. Clonality was evaluated by pulsed-field gel electrophoresis and multilocus sequence typing (Pasteur scheme). Relative expression of β-lactam intrinsic resistance mechanisms was determined for carbapenemase-negative Enterobacteriaceae. ACB and Enterobacteriaceae displayed 58.9 and 0.9% doripenem resistance, respectively. blaOXA-23, blaOXA-58, and blaOXA-24/OXA-40 were detected among 277, 77, and 29 ACB, respectively (in 8, 6, and 5 countries). Ten Turkish isolates carried blaGES-11 or blaGES-22. GES-22 (G243A and M169L mutations in GES-1) had an extended-spectrum β-lactamase profile. A total of 33 clusters of ≥2 ACB isolates were observed, and 227 isolates belonged to sequence type 2/international clone II. Other international clones were limited to Turkey and Israel. Doripenem-resistant Enterobacteriaceae increased significantly (0.7 to 1.6%), and 15 blaKPC-2- and 22 blaKPC-3-carrying isolates, mostly belonging to clonal complexes 11 and 258, were observed. Enterobacteriaceae isolates producing OXA-48 (n = 16; in Turkey and Italy), VIM-1 (n = 10; in Greece, Poland, and Spain), VIM-26 (n = 1; in Greece), and IMP-19, VIM-4, and the novel VIM-35 (n = 1 each from Poland) were detected. VIM-35 had one substitution compared to VIM-1 (A235T) and a similar susceptibility profile. One or more resistance mechanisms were identified in 4/6 carbapenemase-negative Enterobacteriaceae. This broad evaluation confirms results from country-specific surveys and shows a highly diverse population of carbapenemase-producing ACB and Enterobacteriaceae in Europe and Mediterranean countries.

[1]  J. Lavigne,et al.  Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12. , 2014, The Journal of antimicrobial chemotherapy.

[2]  Ronald N. Jones,et al.  Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009-11 in 14 European and Mediterranean countries. , 2014, The Journal of antimicrobial chemotherapy.

[3]  N. Woodford,et al.  NDM carbapenemases in the United Kingdom: an analysis of the first 250 cases. , 2014, The Journal of antimicrobial chemotherapy.

[4]  C. Dunyach-Rémy,et al.  Epidemiology of Carbapenemase-Producing Enterobacteriaceae and Acinetobacter baumannii in Mediterranean Countries , 2014, BioMed research international.

[5]  P. Nordmann,et al.  Worldwide Dissemination of the NDM-Type Carbapenemases in Gram-Negative Bacteria , 2014, BioMed research international.

[6]  J. Campos,et al.  Carbapenemase-Producing Enterobacteriaceae in Spain in 2012 , 2013, Antimicrobial Agents and Chemotherapy.

[7]  N Woodford,et al.  Carbapenemase-producing Enterobacteriaceae in Europe: a survey among national experts from 39 countries, February 2013. , 2013, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[8]  M. Galleni,et al.  Kinetic and Crystallographic Studies of Extended-Spectrum GES-11, GES-12, and GES-14 β-Lactamases , 2012, Antimicrobial Agents and Chemotherapy.

[9]  A. Sundsfjord,et al.  Insights into the global molecular epidemiology of carbapenem non-susceptible clones of Acinetobacter baumannii. , 2012, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  D. Landman,et al.  Transmission of carbapenem-resistant pathogens in New York City hospitals: progress and frustration. , 2012, The Journal of antimicrobial chemotherapy.

[11]  E. Tacconelli,et al.  In Vivo Emergence of Tigecycline Resistance in Multidrug-Resistant Klebsiella pneumoniae and Escherichia coli , 2012, Antimicrobial Agents and Chemotherapy.

[12]  V. Miriagou,et al.  Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[13]  J. Rolain,et al.  Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. , 2012, International journal of antimicrobial agents.

[14]  Thierry Naas,et al.  Global Spread of Carbapenemase-producing Enterobacteriaceae , 2011, Emerging infectious diseases.

[15]  Carlene A. Muto,et al.  Colistin-resistant, Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella pneumoniae belonging to the international epidemic clone ST258. , 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  M. Vaneechoutte,et al.  Genotypic and phenotypic characterization of the Acinetobacter calcoaceticus-Acinetobacter baumannii complex with the proposal of Acinetobacter pittii sp. nov. (formerly Acinetobacter genomic species 3) and Acinetobacter nosocomialis sp. nov. (formerly Acinetobacter genomic species 13TU). , 2011, Research in microbiology.

[17]  R. Koncan,et al.  Identification of a blaVIM-4 gene in the internationally successful Klebsiella pneumoniae ST11 clone and in a Klebsiella oxytoca strain in Hungary. , 2010, The Journal of antimicrobial chemotherapy.

[18]  L. Dijkshoorn,et al.  The Population Structure of Acinetobacter baumannii: Expanding Multiresistant Clones from an Ancestral Susceptible Genetic Pool , 2010, PloS one.

[19]  P. Courvalin,et al.  GES-11, a Novel Integron-Associated GES Variant in Acinetobacter baumannii , 2009, Antimicrobial Agents and Chemotherapy.

[20]  Harald Seifert,et al.  Acinetobacter baumannii: Emergence of a Successful Pathogen , 2008, Clinical Microbiology Reviews.

[21]  V. Miriagou,et al.  Outbreak of Acinetobacter baumannii with Chromosomally Encoded VIM-1 Undetectable by Imipenem-EDTA Synergy Tests , 2008, Antimicrobial Agents and Chemotherapy.

[22]  N. Woodford,et al.  Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp. , 2006, International journal of antimicrobial agents.

[23]  F. Rodríguez-Valera,et al.  Development of a Multilocus Sequence Typing Scheme for Characterization of Clinical Isolates of Acinetobacter baumannii , 2005, Journal of Clinical Microbiology.

[24]  Sylvain Brisse,et al.  Multilocus Sequence Typing of Klebsiella pneumoniae Nosocomial Isolates , 2005, Journal of Clinical Microbiology.

[25]  Ronald N. Jones,et al.  Molecular Characterization of a β-Lactamase Gene, blaGIM-1, Encoding a New Subclass of Metallo-β-Lactamase , 2004, Antimicrobial Agents and Chemotherapy.

[26]  Ronald N. Jones,et al.  Pseudomonas aeruginosa strains harbouring an unusual blaVIM-4 gene cassette isolated from hospitalized children in Poland (1998-2001). , 2004, The Journal of antimicrobial chemotherapy.

[27]  Y. Tselentis,et al.  Spread of blaVIM-1-producing e. coli in a university hospital in Greece. Genetic analysis of the integron carrying the blaVIM-1 metallo-β-lactamase gene , 2004 .

[28]  J. Bartlett,et al.  Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[29]  H. Giamarellou,et al.  Multidrug-Resistant Gram-Negative Infections are the Treatment Options? , 2009 .

[30]  Y. Tselentis,et al.  Spread of bla(VIM-1)-producing E. coli in a university hospital in Greece. Genetic analysis of the integron carrying the bla(VIM-1) metallo-beta-lactamase gene. , 2004, Diagnostic microbiology and infectious disease.

[31]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .